Bluepharma

Bluepharma, a portfolio company of the Portuguese private equity house PME Capital, launched four new generic medications in the national market on October 1. The new products, which were launched by the company’s subsidiary Bluepharma Genéricos, are an anti-allergy medication (Cetirizina), an anti-high blood pressure medication (Atenolol), a medicine for the treatment of high cholesterol (Sinvastatina) and an anti-ulcer product (Omeprazol). All four products have been approved by INFARMED, the Instituto Nacional da Farmácia e do Medicamento. The company will also begin to market a further three generic medicines in Portugal before the end of the year, in addition to the range of products it is already planning to launch in 2004, by which time Portuguese pharmaceutical should account for around 2.5% of the national market. The national medicines market is currently worth around €2m, but is expected to be worth €2.1m in 2004; generic medicines are expected to be worth €116m this year, with a figure of €210m, or a 10% market share, predicted for 2004. Bluepharma began exporting generic medicines to France in 2002, and was one of the first Portuguese pharmaceutical companies to break into the European market.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Southern Europe